Structure Therapeutics Appoints New Director
Ticker: GPCR · Form: 8-K · Filed: Aug 27, 2024 · CIK: 1888886
| Field | Detail |
|---|---|
| Company | Structure Therapeutics Inc. (GPCR) |
| Form Type | 8-K |
| Filed Date | Aug 27, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $45,000, $10,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-appointment, governance
TL;DR
Structure Therapeutics adds Jianmin Feng to its board.
AI Summary
Structure Therapeutics Inc. announced on August 24, 2024, a change in its board of directors. Specifically, Dr. Jianmin Feng has been appointed as a Class II Director, effective immediately. This appointment is part of the company's ongoing governance and strategic direction.
Why It Matters
The appointment of a new director can signal shifts in company strategy, governance, or focus, potentially impacting future business decisions and shareholder value.
Risk Assessment
Risk Level: low — The filing reports a routine board appointment, which typically carries low immediate risk.
Key Players & Entities
- Structure Therapeutics Inc. (company) — Registrant
- Jianmin Feng (person) — Appointed Class II Director
- August 24, 2024 (date) — Effective date of appointment
FAQ
Who is Jianmin Feng and what is their background?
The filing does not provide specific details about Jianmin Feng's background or qualifications, only that they have been appointed as a Class II Director.
What is the significance of being a 'Class II Director'?
The filing does not elaborate on the specific responsibilities or term length associated with being a Class II Director at Structure Therapeutics.
Were there any other changes to the board of directors?
This specific filing (8-K) focuses on the appointment of Jianmin Feng; it does not mention any other departures or appointments on the same date.
What is the effective date of Jianmin Feng's appointment?
Jianmin Feng's appointment as a Class II Director is effective August 24, 2024.
What is the company's primary business?
Structure Therapeutics Inc. is in the Pharmaceutical Preparations industry, as indicated by its SIC code 2834.
Filing Stats: 760 words · 3 min read · ~3 pages · Grade level 11.6 · Accepted 2024-08-27 16:16:05
Key Financial Figures
- $0.0001 — enting three ordinary shares, par value $0.0001 per ordinary share GPCR Nasdaq Glob
- $45,000 — l also receive annual cash retainers of $45,000 for his Board service and $10,000 for h
- $10,000 — rs of $45,000 for his Board service and $10,000 for his service as a member of the Audi
Filing Documents
- tm2422732d1_8k.htm (8-K) — 33KB
- 0001104659-24-093434.txt ( ) — 255KB
- gpcr-20240824.xsd (EX-101.SCH) — 4KB
- gpcr-20240824_def.xml (EX-101.DEF) — 27KB
- gpcr-20240824_lab.xml (EX-101.LAB) — 36KB
- gpcr-20240824_pre.xml (EX-101.PRE) — 25KB
- tm2422732d1_8k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Structure Therapeutics Inc. Date: August 27, 2024 By: /s/ Raymond Stevens Raymond Stevens, Ph.D. Chief Executive Officer